BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang Y, Adams LA, Joseph J, Bulsara MK, Jeffrey GP. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int 2017;37:121-31. [DOI: 10.1111/liv.13116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, Bolimo AF, Tony NJ, Kwenti TE, Wung NH, Nkuo-Akenji T. Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PLoS One 2018;13:e0203312. [PMID: 30183765 DOI: 10.1371/journal.pone.0203312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856 [PMID: 28740596 DOI: 10.4254/wjh.v9.i19.850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
3 Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism 2021;123:154868. [PMID: 34400217 DOI: 10.1016/j.metabol.2021.154868] [Reference Citation Analysis]
4 Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5:40. [PMID: 28251119 DOI: 10.21037/atm.2017.01.28] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
5 Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, Kamada Y, Yoneda M. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis: WFA+-M2BP and liver fibrosis. Journal of Gastroenterology and Hepatology 2017;32:1922-30. [DOI: 10.1111/jgh.13802] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
6 Heidari G, Motamed F, Heirati B, Rahmani P. Diagnostic Performance of Noninvasive Methods for Liver Biopsy by Fibroscan in Pediatric. Journal of Child Science 2021;11:e55-9. [DOI: 10.1055/s-0041-1725079] [Reference Citation Analysis]
7 Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01055-7. [PMID: 34624564 DOI: 10.1016/j.cgh.2021.09.040] [Reference Citation Analysis]
8 Salama SM, Ibrahim IAA, Shahzad N, Al-Ghamdi S, Ayoub N, AlRashdi AS, Abdulla MA, Salehen N, Bilgen M. Hepatoprotectivity of Panduratin A against liver damage: In vivo demonstration with a rat model of cirrhosis induced by thioacetamide. APMIS 2018;126:710-21. [PMID: 30058214 DOI: 10.1111/apm.12878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Lesmana CRA, Paramitha MS, Hasan I, Sulaiman AS, Gani RA. Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment. EMJ. [DOI: 10.33590/emj/21-00039] [Reference Citation Analysis]
11 Wang Z, Huang Y, Nossent H, Chan JJ, Adams LA, Joseph J, Cheng W, Garas G, MacQuillan G, Jeffrey GP. Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study. JGH Open 2020;4:1211-6. [PMID: 33319058 DOI: 10.1002/jgh3.12430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lin B, Ma Y, Wu S, Liu Y, Liu L, Wu L. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. OMICS 2019;23:181-9. [PMID: 30932742 DOI: 10.1089/omi.2019.0035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343-52. [PMID: 32066623 DOI: 10.1136/gutjnl-2018-317593] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
15 Rikhi R, Singh T, Modaresi Esfeh J. Work up of fatty liver by primary care physicians, review. Ann Med Surg (Lond) 2020;50:41-8. [PMID: 31993196 DOI: 10.1016/j.amsu.2020.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
18 Addolorato G, Abenavoli L, Dallio M, Federico A, Germani G, Gitto S, Leandro G, Loguercio C, Marra F, Stasi E. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2020;52:374-91. [PMID: 32001151 DOI: 10.1016/j.dld.2019.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Zhang X, Jie Y, Wan Z, Lin S, Li Y, Lin M, Wu S, Wu X, Shi M, Xiao H, Cao M, Gong J, Chi X. Prognostic Value of Inflammatory Indicators in Chronic Hepatitis B Patients With Significant Liver Fibrosis: A Multicenter Study in China. Front Pharmacol 2021;12:653751. [PMID: 34858162 DOI: 10.3389/fphar.2021.653751] [Reference Citation Analysis]
20 Mik P, Tonar Z, Malečková A, Eberlová L, Liška V, Pálek R, Rosendorf J, Jiřík M, Mírka H, Králíčková M, Witter K. Distribution of Connective Tissue in the Male and Female Porcine Liver: Histological Mapping and Recommendations for Sampling. J Comp Pathol 2018;162:1-13. [PMID: 30060837 DOI: 10.1016/j.jcpa.2018.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Lejealle C, Castera L. Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. Curr Hepatology Rep 2018;17:492-501. [DOI: 10.1007/s11901-018-0439-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Lizaola B, Bonder A, Tapper EB, Afdhal N. Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. Curr Hepatology Rep 2016;15:220-9. [DOI: 10.1007/s11901-016-0311-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Han Y, Zhou Y, Shan T, Li W, Liu H, Gao Y. Immunomodulatory Effect of Lycium barbarum Polysaccharides against Liver Fibrosis Based on the Intelligent Medical Internet of Things. Journal of Healthcare Engineering 2022;2022:1-13. [DOI: 10.1155/2022/6280265] [Reference Citation Analysis]
24 Hamesch K, Mandorfer M, Pereira VM, Moeller LS, Pons M, Dolman GE, Reichert MC, Schneider CV, Woditsch V, Voss J, Lindhauer C, Fromme M, Spivak I, Guldiken N, Zhou B, Arslanow A, Schaefer B, Zoller H, Aigner E, Reiberger T, Wetzel M, Siegmund B, Simões C, Gaspar R, Maia L, Costa D, Bento-miranda M, van Helden J, Yagmur E, Bzdok D, Stolk J, Gleiber W, Knipel V, Windisch W, Mahadeva R, Bals R, Koczulla R, Barrecheguren M, Miravitlles M, Janciauskiene S, Stickel F, Lammert F, Liberal R, Genesca J, Griffiths WJ, Trauner M, Krag A, Trautwein C, Strnad P. Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology 2019;157:705-719.e18. [DOI: 10.1053/j.gastro.2019.05.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
25 Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP. Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol 2020;18:496-504.e3. [PMID: 31319186 DOI: 10.1016/j.cgh.2019.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]